The Assessment of Antiangiogenic and Antivascular Therapies in Early-stage Clinical Trials Using Magnetic Resonance Imaging: Issues and Recommendations

Overview

Journal Br J Cancer

Specialty Oncology

Date 2005 May 5

PMID 15870830

Citations 165

Authors

M O Leach

K M Brindle

J L Evelhoch

J R Griffiths

M R Horsman

A Jackson

G C Jayson

I R Judson

M V Knopp

R J Maxwell

D McIntyre

A R Padhani

P Price

R Rathbone

G J Rustin

P S Tofts

G M Tozer

W Vennart

J C Waterton

S R Williams

P Workman

Affiliations

Soon will be listed here.

Abstract

Vascular and angiogenic processes provide an important target for novel cancer therapeutics. Dynamic contrast-enhanced magnetic resonance imaging is being used increasingly to noninvasively monitor the action of these therapeutics in early-stage clinical trials. This publication reports the outcome of a workshop that considered the methodology and design of magnetic resonance studies, recommending how this new tool might best be used.

Citing Articles

Study of Complete Surgical Response of Stage III Oral Carcinoma Patients in Comparison to Primary Surgery Versus Neoadjuvant Methotrexate With Surgery.

Lonare S, Babu V, Sharma R, Chendkapure K, Velip A, Bind N Cureus. 2024; 16(10):e72680.

PMID: 39478765 PMC: 11523190. DOI: 10.7759/cureus.72680.

Early therapy evaluation of intra-arterial trastuzumab injection in a human breast cancer xenograft model using multiparametric MR imaging.

Kim B, Kim B, You S, Jang M, Im G, Kim K PLoS One. 2024; 19(5):e0300171.

PMID: 38701062 PMC: 11068173. DOI: 10.1371/journal.pone.0300171.

Zhang Y, Wang F, Huang Y Clinics (Sao Paulo). 2024; 79:100367.

PMID: 38692010 PMC: 11070665. DOI: 10.1016/j.clinsp.2024.100367.

Correlation of Perfusion Metrics with Ki-67 Proliferation Index and Axillary Involvement as a Prognostic Marker in Breast Carcinoma Cases: A Dynamic Contrast-Enhanced Perfusion MRI Study.

Uncu U, Aydin Aksu S Diagnostics (Basel). 2023; 13(20).

PMID: 37892081 PMC: 10606869. DOI: 10.3390/diagnostics13203260.

A Review on the Use of Imaging Biomarkers in Oncology Clinical Trials: Quality Assurance Strategies for Technical Validation.

Chauvie S, Mazzoni L, ODoherty J Tomography. 2023; 9(5):1876-1902.

PMID: 37888741 PMC: 10610870. DOI: 10.3390/tomography9050149.

References

Mayr N, Yuh W, Arnholt J, Ehrhardt J, Sorosky J, Magnotta V . Pixel analysis of MR perfusion imaging in predicting radiation therapy outcome in cervical cancer. J Magn Reson Imaging. 2000; 12(6):1027-33. DOI: 10.1002/1522-2586(200012)12:6<1027::aid-jmri31>3.0.co;2-5. View

Padhani A, MacVicar A, Gapinski C, Dearnaley D, Parker G, Suckling J . Effects of androgen deprivation on prostatic morphology and vascular permeability evaluated with mr imaging. Radiology. 2001; 218(2):365-74. DOI: 10.1148/radiology.218.2.r01ja04365. View

Workman P . How much gets there and what does it do?: The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development. Curr Pharm Des. 2003; 9(11):891-902. DOI: 10.2174/1381612033455279. View

Hennig J, Speck O, Koch M, Weiller C . Functional magnetic resonance imaging: a review of methodological aspects and clinical applications. J Magn Reson Imaging. 2003; 18(1):1-15. DOI: 10.1002/jmri.10330. View

Galbraith S, Maxwell R, Lodge M, Tozer G, Wilson J, Taylor N . Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol. 2003; 21(15):2831-42. DOI: 10.1200/JCO.2003.05.187. View

Newell D, Searle K, Westwood N, Burtles S . Professor Tom Connors and the development of novel cancer therapies by the Phase I/II Clinical Trials Committee of Cancer Research UK. Br J Cancer. 2003; 89(3):437-54. PMC: 2394365. DOI: 10.1038/sj.bjc.6601106. View

Yang J, Haworth L, Sherry R, Hwu P, Schwartzentruber D, Topalian S . A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003; 349(5):427-34. PMC: 2275324. DOI: 10.1056/NEJMoa021491. View

Neeman M, Dafni H . Structural, functional, and molecular MR imaging of the microvasculature. Annu Rev Biomed Eng. 2003; 5:29-56. DOI: 10.1146/annurev.bioeng.5.040202.121606. View

Morgan B, Thomas A, Drevs J, Hennig J, Buchert M, Jivan A . Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer.... J Clin Oncol. 2003; 21(21):3955-64. DOI: 10.1200/JCO.2003.08.092. View

10.

Schneider G, Uder M . Contrast-enhanced magnetic resonance body imaging 5. Top Magn Reson Imaging. 2003; 14(5):403-25. DOI: 10.1097/00002142-200310000-00006. View

11.

Strecker R, Scheffler K, Buchert M, Mross K, Drevs J, Hennig J . DCE-MRI in clinical trials: data acquisition techniques and analysis methods. Int J Clin Pharmacol Ther. 2003; 41(12):603-5. DOI: 10.5414/cpp41603. View

12.

Thorpe P . Vascular targeting agents as cancer therapeutics. Clin Cancer Res. 2004; 10(2):415-27. DOI: 10.1158/1078-0432.ccr-0642-03. View

13.

Alessi P, Ebbinghaus C, Neri D . Molecular targeting of angiogenesis. Biochim Biophys Acta. 2004; 1654(1):39-49. DOI: 10.1016/j.bbcan.2003.08.001. View

14.

Verheul H, Pinedo H . Vascular endothelial growth factor and its inhibitors. Drugs Today (Barc). 2004; 39 Suppl C:81-93. View

15.

Cao Y . Antiangiogenic cancer therapy. Semin Cancer Biol. 2004; 14(2):139-45. DOI: 10.1016/j.semcancer.2003.09.018. View

16.

Kohn E, Lu Y, Wang H, Yu Q, Yu S, Hall H . Molecular therapeutics: promise and challenges. Semin Oncol. 2004; 31(1 Suppl 3):39-53. DOI: 10.1053/j.seminoncol.2004.01.009. View

17.

Johnson G, Wetzel S, Cha S, Babb J, Tofts P . Measuring blood volume and vascular transfer constant from dynamic, T(2)*-weighted contrast-enhanced MRI. Magn Reson Med. 2004; 51(5):961-8. DOI: 10.1002/mrm.20049. View

18.

Siemann D, Chaplin D, Horsman M . Vascular-targeting therapies for treatment of malignant disease. Cancer. 2004; 100(12):2491-9. DOI: 10.1002/cncr.20299. View

19.

Turetschek K, Preda A, Novikov V, Brasch R, Weinmann H, Wunderbaldinger P . Tumor microvascular changes in antiangiogenic treatment: assessment by magnetic resonance contrast media of different molecular weights. J Magn Reson Imaging. 2004; 20(1):138-44. DOI: 10.1002/jmri.20049. View

20.

Leach M, Brindle K, Evelhoch J, Griffiths J, Horsman M, Jackson A . Assessment of antiangiogenic and antivascular therapeutics using MRI: recommendations for appropriate methodology for clinical trials. Br J Radiol. 2004; 76 Spec No 1:S87-91. DOI: 10.1259/bjr/15917261. View